A phase 1 clinical trial assessing VTP-1000, an investigational targeted immunotherapy designed to prevent or reduce celiac disease symptoms from accidental gluten exposure by promoting tolerance to gluten.   

The study is being conducted in two parts: Part A and Part B. Part A of the study is fully enrolled; therefore, all eligible participants will be assigned to screen for Part B. There will be a screening period of up to 35 days (1 visit) to confirm eligibility. 

Part B lasts 2 months with 9 visits to the study site. Participants will receive 3 doses of the study drug or placebo over 30 days (1 dose every 2 weeks) and complete a one-day single-dose gluten challenge. Follow-up visits and phone calls will take place after each dose and the gluten challenge. 

Participants will also be asked to complete other activities (e.g., symptom diary, blood tests) to monitor symptoms and health. Compensation for time and travel may be available. 

You are not required to participate if you qualify for this study. Participation is voluntary; you can change your mind and withdraw from the study at any time. 

Please select Continue if you are interested in finding out if you may qualify for this study.